

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1. (Currently Amended) A medicament for prophylactic and/or therapeutic treatment of arteriosclerosis or a vascular disease due to intravascular physical injury, which comprises 4-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]carbamoyl]benzoic acid or a salt thereof as an active ingredient ~~a substance selected from the group consisting of a retinoid and an agent for controlling an action of a retinoid, wherein said substance has substantially no antiproliferative action on vascular endothelial cells, but substantially has antiproliferative action on vascular smooth muscle cells.~~

2. (Currently Amended) A method of treating ~~The medicament according to claim 1,~~ wherein ~~the vascular disease is selected from the group consisting of~~ arteriosclerosis, ~~a cerebrovascular disorder, and~~ or a vascular disease due to intravascular physical injury comprising administering to a mammal an effective amount of 4-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]carbamoyl]benzoic acid or a salt thereof as an active ingredient.

3. (Currently Amended) ~~The medicament method~~ according to claim 2, wherein the vascular disease due to intravascular physical injury is vascular restenosis and/or

reocclusion after percutaneous transluminal coronary angioplasty using an intravascular stent.

4. (Currently Amended) The ~~medicament~~ method according to claim 3, ~~which is wherein the active ingredient is~~ contained in an intravascular stent or a balloon catheter in a form that enables a sustained release of said active ingredient ~~medicament~~.

5. (Currently Amended) The ~~method~~ medicament according to ~~claim 1~~ claim 2, wherein ~~the substance as~~ the active ingredient is 4-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]carbamoyl]benzoic acid ~~or a salt thereof, or 4-[[[3,5-bis(trimethylsilyl)phenyl]carbonylamino]benzoic acid or a salt thereof.~~

6. (Currently Amended) A ~~medicament~~ method for suppressing granulation due to intravascular physical injury, which comprises administering to a mammal an effective amount of a substance comprising 4-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]carbamoyl]benzoic acid or a salt thereof ~~a substance selected from the group consisting of a retinoid and an agent for controlling an action of a retinoid as an active ingredient.~~

7. (Currently Amended) The ~~medicament~~ method according to claim 6, wherein the substance has substantial antiproliferative action on neointima of an injured blood vessel.

8. (Currently Amended) A ~~medicament~~ method for suppressing proliferation of neointima due to intravascular physical injury, which comprises administering to a mammal an effective amount of a substance comprising 4-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]carbamoyl]benzoic acid or a salt thereof ~~a substance selected from the group consisting of a retinoid and an agent for controlling an action of a retinoid as an active ingredient.~~

9. (Currently Amended) A ~~medicament~~ method for prophylactic and/or therapeutic treatment of hypercardia, which comprises administering to a mammal an effective amount of a substance comprising 4-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]carbamoyl]benzoic acid or a salt thereof ~~a substance selected from the group consisting of a retinoid and an agent for controlling an action of a retinoid as an active ingredient.~~

10. (Currently Amended) A ~~medicament~~ method for suppressing fibrosis in hypercardia, which comprises administering to a mammal an effective amount of a substance comprising 4-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]carbamoyl]benzoic acid or a salt thereof ~~a substance selected from the group consisting of a retinoid and an agent for controlling an action of a retinoid as an active ingredient.~~

11. (Currently Amended) The ~~medicament~~ method according to claim 6, wherein the substance as the active ingredient is 4-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-

naphthalenyl]carbonyl]benzoic acid ~~or a salt thereof, or 4-[[[3,5-bis(trimethylsilyl)-~~  
~~phenyl]carbonyl]amino]benzoic acid or a salt thereof.~~

12. (Cancelled)

13. (New) The method according to claim 2, wherein the mammal is a human.

14. (New) The method according to claim 6, wherein the mammal is a human.